https://en.wikipedia.org/wiki/Visual_prosthesis

A visual prosthesis, often referred to as a bionic eye, is an experimental visual device intended to restore functional vision in those with partial or total blindness. 

Ongoing projects

Argus retinal prosthesis project

Argus II was approved for commercial use in Europe, and Second Sight launched the product later that same year. The Argus II was approved by the United States FDA on 14 February 2013.

Harvard/MIT Retinal Implant

Joseph Rizzo and John Wyatt at the Massachusetts Eye and Ear Infirmary and MIT began researching the feasibility of a retinal prosthesis in 1989, and performed a number of proof-of-concept epiretinal stimulation trials on blind volunteers between 1998 and 2000. They have since developed a subretinal stimulator, an array of electrodes, that is placed beneath the retina in the subretinal space and receives image signals beamed from a camera mounted on a pair of glasses. The stimulator chip decodes the picture information beamed from the camera and stimulates retinal ganglion cells accordingly. Their second generation prosthesis collects data and sends it to the implant through radio frequency fields from transmitter coils that are mounted on the glasses. A secondary receiver coil is sutured around the iris.

Photovoltaic retinal prosthesis (PRIMA)

Daniel Palanker and his group at Stanford University developed a photovoltaic retinal prosthesis in 2012,^[32] that includes a subretinal photodiode array and an infrared image projection system mounted on video goggles. Images captured by video camera are processed in a pocket PC and displayed on video goggles using pulsed near-infrared (IR, 880–915 nm) light. These images are projected onto the retina via natural eye optics, and photodiodes in the subretinal implant convert light into pulsed bi-phasic electric current in each pixel.^[33] Electric current flowing through the tissue between the active and return electrode in each pixel stimulates the nearby inner retinal neurons, primarily the bipolar cells, which transmit excitatory responses to the retinal ganglion cells. This technology is being commercialized by Pixium Vision (PRIMA Archived 23 October 2018 at the Wayback Machine), and is being evaluated in a clinical trial (2018). Following this proof of concept, Palanker group is focusing now on developing pixels smaller than 50μm using 3-D electrodes and utilizing the effect of retinal migration into voids in the subretinal implant.

About Bionic Vision Technologies

Bionic Vision Technologies has developed the BVT Bionic Eye System, the world’s first suprachoroidal visual implant, to restore functional vision to the blind suffering from inherited retinal diseases.
The Company has recently completed initial human testing in seven patients demonstrating safety and efficacy with positive outcomes in patient mobility and device stability/durability.
We intend to initiate a worldwide clinical trial in key markets, including Australia, USA and Europe, with commercialization anticipated soon after.

Lets say that here we have some good progress in the field of artifitial eye. But we are still far away from the whole eye implant that can replace the human eye completly.